The European Medicines Agency (EMA) has issued a recommendation to update the antigenic composition of authorised COVID-19 vaccines for the 2026-2027 season, aiming to better protect against circulating variants. The recommendation, published on 29 May 2026, targets vaccine manufacturers and national health authorities as they prepare for the next vaccination campaign.
The document, produced by EMA's Emergency Task Force (ETF), advises that vaccines should target a monovalent JN.1 lineage, specifically the JN.1 or KP.2 variant, to ensure broad protection against currently dominant Omicron sublineages. This follows the World Health Organization's (WHO) similar recommendation in April 2026. The EMA's guidance is non-binding but is expected to be adopted by the European Commission and national regulators.
Policy orientations and trade-offs The EMA's recommendation balances the need for updated protection against the risk of delaying vaccine availability. Targeting a more recent variant like KP.2 may offer better neutralisation but could slow production, while a JN.1-based vaccine is easier to manufacture quickly. The agency also considered the potential for future variant evolution, urging flexibility in the manufacturing process.
Impact on stakeholders - Vaccine manufacturers (Pfizer/BioNTech, Moderna, Novavax, Sanofi/GSK): Must adapt their production lines to the new antigen composition, incurring costs and potential delays. The recommendation provides clarity but also pressure to deliver updated doses by autumn 2026. - National health authorities: Will need to update their procurement and vaccination strategies, ensuring sufficient supply of the updated vaccines for at-risk populations. - EU citizens, especially vulnerable groups: Stand to benefit from improved protection against current variants, but may face confusion if multiple variant-specific vaccines are offered. - EMA and EU regulatory bodies: The recommendation reinforces EMA's role in coordinating pandemic response, but any mismatch between the chosen variant and future circulating strains could undermine public trust.
Expected institutional follow-up The European Commission is expected to endorse the EMA recommendation within weeks, triggering contract amendments with vaccine suppliers. National vaccination campaigns are likely to begin in September or October 2026, depending on manufacturing timelines and regulatory approvals.
← Atlas › News › Health & Lifestyle